He is board-certified in anatomic pathology, dermatopathology and hematopathology, and studies prognostic markers in cutaneous T cell lymphomas utilizing next generation sequencing, and the effects of Toll-Like Receptors on tumor pathogenesis in melanoma and other cancers. His work has been funded by the NIH and private foundations.